ReviewInternational journal of molecular sciences2026
Neurotrophin System as a Complex Set of Potential Biomarkers in Psychiatric Disorders and Therapy-Overview of Recent Advances.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neurotrophin system has numerous regulatory roles in the central nervous system, including the growth, differentiation, and survival of neurons, the control of neurogenesis, synaptic plasticity, and the mediation of neurotransmitter balance, also with proven anti-inflammatory, anti-apoptotic, and antioxidative actions. These functions are seriously affected by numerous pathophysiological processes accompanied by mental illness. The variety of therapeutic protocols (pharmacotherapy, transcranial stimulation, psychotherapy, lifestyle changes, programmed physical activity, dietary interventions), individually or in combination, has been employed in the treatment of psychiatric disorders. To evaluate the effectiveness of therapeutic strategies, specific elements of the neurotrophin system have been quantified to assess their potential as biomarkers. However, data obtained in clinical trials for different psychiatric disorders still do not confirm the reliability of neurotrophin system elements as biomarkers. For this purpose, we aimed this narrative review to explore clinical studies published in the last decade that examined neurotrophin system elements in patients with various psychiatric disorders, with a focus on their association with disease severity, clinical state, and treatment response, which represents a promising avenue for improving our understanding of the underlying mechanisms and for identifying potential clinically relevant biomarkers, as well as sharpening therapeutic protocol outcome analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.